Thursday, 8 February 2018

Cancer-causing HPV can reside in throat

Researchers at the University of Rochester Medical Center in New York claim that the HPV "virus could be present in people's throats without people aware that they're carriers."  While it is believed that only 5% of individuals with HPV will develop cancer of the mouth or throat, the researchers do expect that cases of head and neck cancer will outnumber cervical cancer cases by 2020.  Thus, according to study author Dr. Matthew Miller, the findings observed at Rochester "could have far-reaching implications for identifying people at risk of developing HPV-related head and neck cancers and ultimately preventing them."

To read more about this study, click here.

Thursday, 1 February 2018

Cancer survival rates vary across the world

A new study published in the January 30 issue of The Lancet shows that while cancer survival rates are, in general, improving worldwide, diversity continues to exist between wealthy and poor countries.  Conducted from 2000-2014, the study assessed "five-year cancer survival rates among 37.5 million children and adults diagnosed with one of 18 common cancers." from 71 countries and territories.  Of significant note is the 5-year survival rate of breast cancer, brain tumour, and lung cancer; breast cancer survival has risen to 90% in the USA and Australia vs. 66% in India; brain tumour survival in children is listed as 80% in Denmark and Sweden, but less than 40% in Mexico and Brazil; lung cancer survival rates have risen from 7%-13% in the United Kingdom, with significant increases in China (from 8%-20%), Japan (23%-33%) and Korea (10%-25%).

To read more about this study, click here.

Friday, 26 January 2018

New treatments for lung cancer

A new report authored by a team at the Yale Cancer Center presents a synopsis of lung cancer treatments over the past 20 years.  According to co-lead author Dr. Roy Herbst, chief of medical oncology at Yale Cancer Center, "options for treatments have improved in recent years with the advent of two classes of drugs - molecularly targeted therapies, and more recently, immunotherapies."

To read more about this report, click here.

Saturday, 20 January 2018

Blood test could detect cancer in early stages

Scientists at Johns Hopkins University are currently testing a blood test purported to detected several cancers, including ovary, liver, stomach, pancreas, oesophagus, colorectal, lung, and breast, at early stages.  Known as liquid biopsies, the tests "look for DNA and other things that tumours she into blood, to try to find cancer before it spreads, when chances of cure are best."  While the test is not ready for use yet, it is seen as a significant step towards early detection of cancer before tumours can spread.

To read more about this blood test, click here.

Wednesday, 17 January 2018

BRCA breast cancer gene doesn't affect patient survival

A new study conducted by the NHS Foundation Trust in England indicates that there is no distinction in survival rates between young breast cancer patients with a BRCA gene mutation and those without.  The study was conducted on more than 2,700 women in the United Kingdom between 18-40 years old, with a first-time breast cancer diagnosis.  12% of the women studied had a BRCA mutation, however lead researcher Diana Eccles stated that findings showed "survival rates after 2 years were 97% for women with a BRCA mutation and 96.6% for those without the mutation."

To read more about this study, click here.

Monday, 8 January 2018

Medicinal cream may aid in recurrence of skin cancer

A study conducted at Brown University in Providence, Rhode Island on 930 U.S. veterans, with an average age of 70, indicates that a generic cream known as 5-FU  can reduce recurrence of skin cancer.  According to study results, "just a month's application of 5-FU (fluorouracil 5%) appeared to have a lasting impact in preventing a recurrence - even after use of the cream was stopped." Despite these findings, many dermatologists caution against the side effects associated with 5-FU, including redness, scaling, irritation and plain, which affects ~ 40% of those applying the medicinal cream.

To read more about this study, click here.

Tuesday, 2 January 2018

Clinical trial alert: comparison of endoscopic visualization and CT imaging of head and neck cancers with pathological validation

A new clinical trial, sponsored by the University Health Network in Toronto, discusses endoscopy as a new method of optimal imaging for radiation therapy in head and neck cancer patients. This method is particular important, as "radiation needs to cover the entire tumour while minimizing the amount of normal tissue that is exposed to radiation.

To read more about this trial, click here.

Friday, 22 December 2017

Blog posts will resume in January 2018 - Happy Holidays

To all Grey Horizon readers:

Thank you for supporting our blog these past 5 years.  Postings will resume in January 2018.

Thank you and Happy Holidays!

Wednesday, 20 December 2017

Electric cap device offers hope to glioblastoma patients

A recent CTV news report introduced an electric cap-like device for patients with glioblastoma, an aggressive brain cancer with a 5-year survival rate of only 5%.  Known as Optune, the device, which is worn by patients 18 hours per day, "emits a low-intensity electromagnetic field to stop or slow cancer cells from dividing."  Regular use of the device has increased life expectancy by 4 months, however it has also increased the survival rate after 5 years to 13%.

To read more about this news story, click here.

Cancer survivors often age prematurely

Mayo Clinic researchers have recently conducted a study indicating that cancer survivors are often susceptible to premature aging following treatment.  Long-term health problems include "hormone and gland disorders, heart problems, brittle bones, lung scarring, and new cancers."

To read more about this study, click here.

Monday, 18 December 2017

New cancer drug shows promise against wide range of tumors

A preliminary trial, conducted at Massachusetts General Hospital is showing promise against many different tumor types.  Known as ulixertinib, the drug was administered to 135 cancer patients who had failed treatments for a variety of advanced, solid tumors.  According to the trial, ulixertinib "inhibits the MAPK/ERK pathway...a chain of proteins in the cell that communicates a signal from a receptor on the surface of the cell to the DNA in the nucleus of the cell."

To read more about this trial, click here

Friday, 15 December 2017

Prior cancers common in patients newly diagnosed with cancer

A new study conducted at the University of Texas Southwestern Medical Center in Dallas indicates that between 2009 and 2013, nearly 20% of patients newly diagnosed with cancer had a previous history of cancer diagnosis.  According to lead author Dr. Caitlyn Murphy, "some types of second primary cancer - such as leukemia - can be related to chemotherapy or radiation therapy used to treat a prior cancer", necessitating that clinicians be aware of these possible links when caring for cancer survivors.

To read more about this study, click here.

Thursday, 14 December 2017

New trial alert: Ipatasertib in combination with Paclitaxel as a treatment for patients with PIK3CA/AKT1/PTEN-altered, locally advanced or metastatic, triple-negative breast cancer

A new clinical trial, being conducted at Sunnybrook Health Sciences Centre in Toronto, is seeking to evaluate the efficiency of ipatasertib + paclitaxel in patients with locally advanced or metastatic triple-negative breast cancer. The primary outcome of this investigation is progression-free survival, while secondary outcomes include health status, health-related quality of life, incidence and severity of adverse events, and changes in vital signs. This trial is currently in pending status, with an anticipated December 2017 start date.

To read more about this trial, click here.

Thursday, 7 December 2017

Acupuncture may ease pain tied to breast cancer care

New research conducted at the Breast Cancer Program, Presbyterian/Columbia University Medical Center in New York City indicates that acupuncture may ease joint pain, a common side effect of breast cancer medications. According to Dr. Lauren Cassell, chief of breast surgery at Lenox Hill Hospital in New York, "if something so simple as acupuncture can improve...symptoms and the patients' quality of life, we will have more women becoming compliant in taking their medication."

To read more about this research, click here. 

Saturday, 2 December 2017

Gum disease tied to esophageal cancer

A new study conducted at NYU Langone Health in New York City has drawn a correlation between gun disease bacteria and the risk of developing esophageal cancer.  The study, conducted on 122,000 Americans who's oral health was observed over a period of 10 years found that "the presence of one oral bacterium in particular, Tannerella forsythia...led to a 21% increase in the odds of developing esophageal tumors."  This find noted emphasized the importance of regularly brushing, flossing, and dental visits.

To read more about this study, click here.

Wednesday, 29 November 2017

6% of cancers caused by excess weight and diabetes

A new report conducted at Imperial College in London indicates that excess weight and diabetes is a direct cause of 6% of cancers worldwide.  According to lead author Dr. Jonathan Pearson-Stuttard, the report analyzed health data from 175 countries, concluding that "5.6% of new cancers care..were caused by high body mass index (BMI) and diabetes."

To read more about the report, click here.

Tuesday, 21 November 2017

Cancer survivors can develop post-traumatic stress disorder (PTSD)

New research conducted at the National University of Malaysia indicates that the trauma endured by cancer survivors can lead them to develop post-traumatic stress disorder (PTSD).  According to lead researcher Caryn Mai Hsien Chan, the study, conducted on 469 adults with different types of cancer, "showed that nearly 22% had symptoms of PTSD six months after their cancer diagnosis...6% still had the condition four years after diagnosis." 

To read more about this study, click here.

Saturday, 18 November 2017

University of Calgary receives additional funding from Canadian Institutes of Health Research for cancer care

The University of Calgary has received a portion of a $5.7 million grant from the Canadian Institutes of Health Research (CIHR) to study and develop better cancer care.  According to the news release, Dr. Jessica E. Simon will "lead a study how community-based palliative care can help patients with non-curable colorectal cancer and demonstrate the effectiveness early care has."

To read more about this funding, click here.

Friday, 10 November 2017

Low-fat diet may reduce pancreatic cancer risk for older overweight women

A new study conducted at the Baylor College of Medicine in Houston, Texas suggests that a low-fat diet may reduce risk of pancreatic cancer among women between 50-79 that are overweight or obese. According to the study's first author, Dr. Li Jiao, 46,000 overweight and obese women were part of a clinical trial held between 1993-1998.  After 15 years of follow-up, 92 cases of pancreatic cancer occurred following a low-fat diet, compared to 165 cases in the comparison group.

To read more about this study, click here.

Tuesday, 7 November 2017

Blood thinner may lower cancer risk

New research being conducted at the University of Bergen in Norway indicates that Warfarin, a commonly prescribed blood thinner may lower the risk of developing cancer.  While lead researcher James Lorens cautioned that the observational study, conducted on 1.25 million Norwegian people aged 50 and older, does not "prove a cause and effect relationship...[that] warfarin reduced the risk of cancer", cancer models have determined that warfarin blocks the AXL receptor on tumor cells.

To read more about this report, click here.


Thursday, 2 November 2017

Some heartburn medication may be linked to stomach cancer

A new study from the University of Hong Kong indicates tat regular prolonged use of certain heartburn medications, known as proton pump inhibitors (PPIs) may increase the risk of stomach cancer.  According to lead researcher Dr. Wai Keung Leung, "while PPIs are one of the most commonly used medications for treating reflex disease...clinicians should exercise caution when prescribing long-term PPIs..."

To read more about this study, click here.

Wednesday, 1 November 2017

Should colon cancer screening began at an earlier age?

A new French study from the Clinique de Bercy in Charenton-le-Pont, has proposed that earlier screening (i.e. at age 45 instead of age 50) be undertaken for colon cancer.  The study, conducted on 6,000 patients who had a colonoscopy, determined that "among 45-49 year-old patients, 26% showed growth called adenomas...compared to 13% of patients ages 40 to 44."  Lead researcher Dr. David Karsenti, who presented the findings at the October 30th United European Gastroenterology Meeting in Barcelona, Spain feels that delaying screening until age 50 could limit some patients' odds of surviving a colon cancer diagnosis.

To read more about this study, click here.

Tuesday, 31 October 2017

Gene therapy may prevent brain cancer recurrence

 A new phase I clinical trial conducted at the University of Minnesota Medical School  indicates that gene therapy treatment may prevent the recurrence of brain cancer cancer.  The trial, conducted on 56 patients with recurrent high-grade glioma brain cancer shows that "3 years after the gene therapy treatment, more than a quarter of the patients were still alive."  Median survival time for patients was raised to 14.4 months, compared to 8 months for patients without the gene therapy.

Click here to read more about this trial, results of which were presented on Friday, October 27th at the International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia.

Wednesday, 18 October 2017

new trial alert: Walk on: a community-based approach to promote participation in physical activity among men treated for colorectal cancer

The Wellness Beyond Cancer Program at the Ottawa Hospital is recruiting men 18 years or older, diagnosed with colorectal cancer and having completed treatment, to participate in a clinical trial.  The primary purpose of the trial is to determine if a "men's group-based walking program [could be] an effective way to reach men and promote quality of life after cancer treatment."

To read more about this trial, click here.

Artificial intelligence as a possible partner in breast cancer care

New research conducted at the Massachusetts General Hospital suggests that artificial intelligence can help doctors identify high-risk breast lesions that could manifest into cancer. According to study author Dr. Manisha Bahi, the machine learning test involved 1,000 women with high-risk breast lesions, identifying 37 of 38 lesions correctly. 

To read more about this study, click here.

Friday, 6 October 2017

How breast cancer gene mutations raise risk of tumours

Researchers at the Yale Cancer Center claim to have identified the molecular mechanism that enables the mutation to cause the BRCA1 gene to lose its DNA repair and tumour-fighting power" and thus trigger breast cancer.  According to Patrick Sung, study senior author, results from these findings could lead to more effective drugs to treat breast and ovarian cancers.

To read more about this study, click here.

Friday, 29 September 2017

Rituxan may prolong survival of patients with lymphoma

A new clinical trial conducted at Nantes Medical University in France has found that Rituxan (rituximab) can prolong the life of lymphoma patients.  The trial, conducted on 299 patients younger than 66 when first diagnosed with mantle-cell lymphoma determined that "after four years, 83% of rituximab patients were still alive and progression-free, versus 64% of patients who had standard treatment alone."

To read more about this clinical trial, click here.

Monday, 25 September 2017

Yoga can aid sleep difficulty for breast cancer patients

Researchers at the University of Texas MD Anderson Cancer Center's integrative medicine program  have shown that practicing Tibetan yoga benefits breast cancer patients with sleeping difficulties.  The study, conducted on 227 women receiving chemotherapy for breast cancer, found that those who practice Tibetan yoga over the course of 4 75-90 minutes classes, taught one-on-one by a trained instructor, "reported fewer sleep problems and less daytime drowsiness..."

To read more about this study, click here.

Inflammatory bowel disease may raise cancer risk in children

A new study conducted at the Karolinska Institute in Stockholm, Sweden indicates that children afflicted with inflammatory bowel disease (IBD) are at greater risk for developing gastrointestinal cancers as adults.  The international research team, lead by Dr. Ola Olen, a pediatric gastroenterologist at Karolinska found that "the risk of cancer up to an average age of 30 was 3.3 cases per 1,000 person years among those with IBD...compared with 1.5 cases per 1,000 person years in the control group."

To read more about this study, click here.

Thursday, 14 September 2017

Expert panel supports HPV test alone for cervical cancer screening over 30

The U.S. Preventive Services Task Force (USPSTF), a panel of health experts, is supporting use of the HPV test as a routine component for cervical cancer screening.  The panel recommends that "the test for the human papillomavirus (HPV) can be used once every five years for women aged 30 to 65, in lieu of the once every three-year Pap test."  For women younger than 30, aged 21-29, undergoing a Pap test once every 3 years remains the recommended option.

To read more about the USPSTF's views on this issue, click here.